FDA review of dupilumab for chronic spontaneous urticaria

Published Date: 13 Mar 2023

The FDA approval request for CSU is based on data from a pair of Phase 3 trials in two different populations.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

In NSCLC, subcutaneous Lazertinib + Amivantamab Dosing Is Not Worse Than IV Dosing.

2.

When Healthcare Chatbots Fall Short of Human Connection

3.

Quizartinib Benefit in AML Limited to FLT3-Mutated Subgroup

4.

A pilot study investigates a novel strategy for lowering anxiety and enhancing post-stem cell transplant quality of life.

5.

Low-Dose Radiation Provides Almost Perfect Control Over Slow-Growing Lymphoma.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot